Under the banner of Byrne’s nonprofit organization, Arbutus, Reasons to be Cheerful embodies this sensibility, applying it now to the future of our world. Through stories of hope, rooted in evidence, ...

Arbutus Biopharma (ABUS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ed Arce from H.C. Wainwright maintained a Buy rating on the stock ...

Arbutus Biopharma (NASDAQ:ABUS) announced on Monday its 2025 corporate objectives and provided a financial update. The company had cash, cash equivalents and investments in marketable securities ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...